USP7 和 USP47 去泛素化酶调节 NLRP3 炎症小体的激活。
USP7 and USP47 deubiquitinases regulate NLRP3 inflammasome activation.
机构信息
Division of Infection, Immunity and Respiratory Medicine, Faculty of Biology, Medicine and Health, Manchester Collaborative Centre of Inflammation Research, Manchester Academic Health Science Centre, Core Technology Facility, School of Biological Sciences, University of Manchester, Manchester, UK.
Division of Neuroscience and Experimental Psychology, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre School of Biological Sciences University of Manchester, Manchester, UK.
出版信息
EMBO Rep. 2018 Oct;19(10). doi: 10.15252/embr.201744766. Epub 2018 Sep 11.
The assembly and activation of the inflammasomes are tightly regulated by post-translational modifications, including ubiquitin. Deubiquitinases (DUBs) counteract the addition of ubiquitin and are essential regulators of immune signalling pathways, including those acting on the inflammasome. How DUBs control the assembly and activation of inflammasomes is unclear. Here, we show that the DUBs USP7 and USP47 regulate inflammasome activation in macrophages. Chemical inhibition of USP7 and USP47 blocks inflammasome formation, independently of transcription, by preventing ASC oligomerisation and speck formation. We also provide evidence that the ubiquitination status of NLRP3 itself is altered by inhibition of USP7 and USP47. Interestingly, we found that the activity of USP7 and USP47 increased in response to inflammasome activators. Using CRISPR/Cas9 in the macrophage cell line THP-1, we show that inflammasome activation is reduced when both USP7 and USP47 are knocked down. Altogether, these data reveal a new post-transcriptional role for USP47 and USP7 in inflammation by regulating inflammasome activation and the release of the pro-inflammatory cytokines IL-1β and IL-18, and implicate dual USP7 and USP47 inhibitors as potential therapeutic agents for inflammatory disease.
炎性小体的组装和激活受到翻译后修饰的严格调控,包括泛素。去泛素化酶(DUBs)可拮抗泛素的添加,是免疫信号通路的重要调节剂,包括作用于炎性小体的信号通路。DUBs 如何控制炎性小体的组装和激活尚不清楚。在这里,我们表明 DUBs USP7 和 USP47 调节巨噬细胞中的炎性小体激活。USP7 和 USP47 的化学抑制通过阻止 ASC 寡聚化和斑点形成,独立于转录,阻断炎性小体的形成。我们还提供了证据表明,NLRP3 本身的泛素化状态也被 USP7 和 USP47 的抑制所改变。有趣的是,我们发现 USP7 和 USP47 的活性在炎性小体激活剂的作用下增加。在巨噬细胞系 THP-1 中使用 CRISPR/Cas9,我们表明当 USP7 和 USP47 都被敲低时,炎性小体的激活减少。总之,这些数据揭示了 USP47 和 USP7 在炎症中通过调节炎性小体激活和促炎细胞因子 IL-1β 和 IL-18 的释放的新的转录后作用,并暗示双重 USP7 和 USP47 抑制剂可能是炎症性疾病的潜在治疗药物。